Baseline values (mean ± SD) of coagulation parameters, monocyte counts, and tissue factor expression on monocytes in 24 healthy male volunteers before receiving LPS infusion
| Parameter (units) . | Placebo . | Lepirudin . |
|---|---|---|
| Prothrombin fragment (F1+2, nmol/L) | 0.55 ± 0.18 | 0.56 ± 0.15 |
| Thrombus precursor protein (TpP, μg/mL) | 1.8 ± 0.7 | 2.3 ± 1.0 |
| D-dimer (ng/mL) | 222 ± 119 | 347 ± 268 |
| Thrombin-antithrombin complexes (TAT, μg/L) | 1.9 ± 0.3 | 1.7 ± 0.1 |
| Tissue factor pathway inhibitor (TFPI, %) | 85 ± 22 | 81 ± 19 |
| Antithrombin III (AT III, %) | 99 ± 9 | 99 ± 6 |
| Plasmin-α2-antiplasmin complexes (PAP, μg/L) | 347 ± 176 | 451 ± 208 |
| Tissue-type plasminogen activator (t-PA, ng/mL) | 4.5 ± 1.9 | 4.1 ± 1.9 |
| Plasminogen activator inhibitor 1 (PAI-1, ng/mL) | 23 ± 13.6 | 17 ± 12.7 |
| Tissue factor+ monocytes (TF+, %) | 3.9 ± 2.6 | 2.7 ± 1.5 |
| Parameter (units) . | Placebo . | Lepirudin . |
|---|---|---|
| Prothrombin fragment (F1+2, nmol/L) | 0.55 ± 0.18 | 0.56 ± 0.15 |
| Thrombus precursor protein (TpP, μg/mL) | 1.8 ± 0.7 | 2.3 ± 1.0 |
| D-dimer (ng/mL) | 222 ± 119 | 347 ± 268 |
| Thrombin-antithrombin complexes (TAT, μg/L) | 1.9 ± 0.3 | 1.7 ± 0.1 |
| Tissue factor pathway inhibitor (TFPI, %) | 85 ± 22 | 81 ± 19 |
| Antithrombin III (AT III, %) | 99 ± 9 | 99 ± 6 |
| Plasmin-α2-antiplasmin complexes (PAP, μg/L) | 347 ± 176 | 451 ± 208 |
| Tissue-type plasminogen activator (t-PA, ng/mL) | 4.5 ± 1.9 | 4.1 ± 1.9 |
| Plasminogen activator inhibitor 1 (PAI-1, ng/mL) | 23 ± 13.6 | 17 ± 12.7 |
| Tissue factor+ monocytes (TF+, %) | 3.9 ± 2.6 | 2.7 ± 1.5 |